Inotiv (NOTV.Q) Hisse Özeti
Inotiv, Inc. Amerika Birleşik Devletleri, Hollanda ve uluslararası alanda ilaç ve tıbbi cihaz endüstrilerine klinik olmayan ve analitik ilaç keşif ve geliştirme hizmetleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 2/6 |
| Temettüler | 0/6 |
NOTV.Q Community Fair Values
Create NarrativeSee what 42 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Inotiv, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$0.05 |
| 52 Haftanın En Yüksek Seviyesi | US$2.44 |
| 52 Haftanın En Düşük Seviyesi | US$0.026 |
| Beta | 3.77 |
| 1 Aylık Değişim | -84.08% |
| 3 Aylık Değişim | -85.31% |
| 1 Yıllık Değişim | -97.75% |
| 3 Yıllık Değişim | -99.05% |
| 5 Yıllık Değişim | -99.83% |
| Halka arzdan bu yana değişim | -99.39% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 03
NOTV: Future P/E And Margins Will Drive Upside Despite Bankruptcy
Analysts have updated their view on Inotiv with a revised $5.00 price target, citing refreshed assumptions for revenue growth, profit margins, discount rate, and future P/E, which collectively adjust the stock's risk and return profile without changing the headline valuation level. What's in the News Inotiv and multiple affiliates filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on June 3, 2026, with reported assets and liabilities each in the range of US$500m to US$1b.
Anlatı Güncellemesi • May 15
NOTV: Improving Margins And Higher Future P/E Will Support Upside
Analysts have held their fair value estimate for Inotiv steady at $3.25, citing updated assumptions for revenue growth of 5.99%, a profit margin of 15.62%, a discount rate of 12.46% and a future P/E of 1.76x as key inputs behind the maintained target. Valuation Changes Fair Value: Held steady at $3.25, with no change in the model output.Recent updates
Anlatı Güncellemesi • Jun 03
NOTV: Future P/E And Margins Will Drive Upside Despite Bankruptcy
Analysts have updated their view on Inotiv with a revised $5.00 price target, citing refreshed assumptions for revenue growth, profit margins, discount rate, and future P/E, which collectively adjust the stock's risk and return profile without changing the headline valuation level. What's in the News Inotiv and multiple affiliates filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on June 3, 2026, with reported assets and liabilities each in the range of US$500m to US$1b.Anlatı Güncellemesi • May 15
NOTV: Improving Margins And Higher Future P/E Will Support Upside
Analysts have held their fair value estimate for Inotiv steady at $3.25, citing updated assumptions for revenue growth of 5.99%, a profit margin of 15.62%, a discount rate of 12.46% and a future P/E of 1.76x as key inputs behind the maintained target. Valuation Changes Fair Value: Held steady at $3.25, with no change in the model output.Anlatı Güncellemesi • Apr 29
NOTV: Refined Outlook Will Rely On Margin Execution And Future P/E
Narrative Update on Inotiv Analysts reduced their price target on Inotiv by $1.50, aligning the change with updated expectations for slightly different revenue growth, profit margin, and future P/E assumptions. Analyst Commentary The latest move to trim the price target by $1.50 reflects analysts fine tuning their models for Inotiv, with updated assumptions around revenue mix, profitability, and future P/E levels.Anlatı Güncellemesi • Apr 15
NOTV: Margin Execution And Higher Future P/E Will Support Upside
Analysts have trimmed their price target on Inotiv by $1.50 to reflect updated expectations for profit margins and a slightly higher assumed future P/E multiple. Analyst Commentary Recent research suggests that the trimmed price target reflects a recalibration of expectations rather than a complete shift in the investment case for Inotiv.
Anlatı Güncellemesi • Apr 01
NOTV: Future Upside Will Depend On Meeting Nasdaq Bid Price Requirement
Analysts have lowered their price target on Inotiv by $1.50 to reflect updated fair value estimates, a slightly adjusted discount rate, and modest changes to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Bearish analysts lowering the price target by $1.50 are signaling a more cautious stance on how Inotiv is priced relative to updated fair value estimates.Anlatı Güncellemesi • Mar 18
NOTV: Refined Outlook Will Rely On Margin Execution And Nasdaq Compliance
Analysts have reduced their price target on Inotiv by $1.50, citing updated assumptions about slightly different revenue growth, profit margin and future P/E expectations, while maintaining their fair value estimate of $5.00. Analyst Commentary Even with the reduced price target, bullish analysts continue to see a path where the current fair value estimate of $5.00 is supported by Inotiv's revenue profile, margin potential and P/E framework.
Anlatı Güncellemesi • Mar 06
The Global Shortage of Research Primates and Why It May Matter for Inotiv
Non-human primates (NHPs), particularly cynomolgus macaques, remain one of the most important animal models in modern drug development. Their physiological similarity to humans makes them essential for evaluating safety, pharmacokinetics, and toxicity before new drugs enter human clinical trials.Anlatı Güncellemesi • Mar 04
The Hidden Scientific Infrastructure Behind Inotiv.
Introduction In recent years, Inotiv has frequently appeared in the news due to a series of challenges. These include regulatory issues related to the Envigo acquisition, global disruptions in non-human primate supply chains, debt inherited through acquisitions, and even a cybersecurity incident.Anlatı Güncellemesi • Mar 04
NOTV: AI Data Partnership Will Support Future Upside Despite Going Concern Risk
Analysts have reduced their price target on Inotiv by $1.58 to $3.25, citing updated assumptions around fair value, the discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Analysts cutting their target price to US$3.25 are essentially saying their expectations around Inotiv’s execution, growth profile, and risk level have shifted.Anlatı Güncellemesi • Feb 23
Why March 6 and March 31 Matter
— In Light of Inotiv, Inc.’s Eighth Amendment and Recent Institutional Disclosure In recent discussions surrounding Inotiv, Inc. (NASDAQ: NOTV), the dates of March 6 and March 31 have been frequently highlighted as important milestones.Anlatı Güncellemesi • Feb 17
NOTV: Recalibrated Outlook Will Rely On Execution And AI Collaboration
Analysts have reduced their price target for Inotiv by $4.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, which reflect a more cautious but still constructive view on the company. Analyst Commentary Bullish analysts are framing the lower price target as a recalibration of assumptions rather than a loss of confidence in Inotiv.Anlatı Güncellemesi • Feb 13
Inotiv's Margin Discipline Will Reshape Its Financial Future
Inotiv does not need perfection. It needs margin discipline.Yeni Anlatı • Feb 11
Inotiv NAMs Test Center
Dear Inotiv, My name is Jong Ik Kwon, DVM , a graduate of Seoul National University College of Veterinary Medicine. Earlier in my career, I worked for Kwangdong Pharmaceutical as a Clinical Research Manager (CRM) for two years , where I gained direct experience in clinical development, regulatory processes, and pharmaceutical operations.Anlatı Güncellemesi • Feb 03
NOTV: Raised Fair Value Will Rely On AI Collaboration Execution
Analysts have raised their fair value estimate for Inotiv from $2.50 to $3.00, citing updated assumptions on revenue growth, profit margins and future P/E, even as they apply a slightly higher 12.5% discount rate. What's in the News On December 31, 2025, Inotiv received a Nasdaq notification that its common stock did not meet the Minimum Bid Price Rule of a US$1.00 closing bid for 30 consecutive business days, starting a 180 day window, to June 29, 2026, to regain compliance under Listing Rule 5550(a)(2) (Nasdaq notice).Anlatı Güncellemesi • Jan 20
NOTV: AI Data Collaboration Will Drive Upside Despite Going Concern Risk
Analysts have kept their Inotiv price target broadly steady, adjusting their fair value estimate to US$4.83. Small tweaks to profit margin and future P/E assumptions left their overall view largely unchanged.Anlatı Güncellemesi • Jan 06
NOTV: AI Collaboration And Margin Expansion Will Support Upside Despite Going Concern Risk
Analysts have kept their price target for Inotiv steady at US$4.83, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Inotiv and VUGENE announced a collaboration to integrate VUGENE's cloud-based bioinformatics and computational platform into Inotiv's Discovery & Translational Sciences Division, aimed at more efficient analysis of complex biological data across epigenomic, proteomic, and other molecular datasets (Key Developments).Anlatı Güncellemesi • Dec 19
NOTV: Future Margin Improvements Will Support Upside Despite Going Concern Risk
Narrative Update on Inotiv Analysts have modestly raised their price target on Inotiv to approximately $4.83 per share, citing slightly improved long term profit margin expectations and a marginally more attractive future earnings multiple. What's in the News Auditor Ernst & Young issued an unqualified opinion on Inotiv's latest 10 K but raised substantial doubt about the company’s ability to continue as a going concern, highlighting liquidity and sustainability risks for investors (10 K filing).Anlatı Güncellemesi • Dec 05
NOTV: Future Margins And Legal Settlement Will Support Share Upside
Narrative Update on Inotiv Analysts have lowered their average price target on Inotiv by roughly 12 percent, to about $4.83 per share from around $5.50. They cite slightly softer revenue growth assumptions that are only partly offset by expectations for improved profit margins and a lower future earnings multiple.Analiz Makalesi • Jun 27
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 28% Share Price Slump
Inotiv, Inc. ( NASDAQ:NOTV ) shareholders won't be pleased to see that the share price has had a very rough month...Analiz Makalesi • May 03
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 29% Share Price Slump
Unfortunately for some shareholders, the Inotiv, Inc. ( NASDAQ:NOTV ) share price has dived 29% in the last thirty...Analiz Makalesi • Apr 25
Health Check: How Prudently Does Inotiv (NASDAQ:NOTV) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Yeni Anlatı • Apr 06
NHP Facilities And North American Optimization Will Secure Stability
Expanding the non-human primates client base and investments in facilities aim to stabilize revenue and enhance profitability through improved service offerings.Analiz Makalesi • Mar 11
Market Cool On Inotiv, Inc.'s (NASDAQ:NOTV) Revenues Pushing Shares 32% Lower
To the annoyance of some shareholders, Inotiv, Inc. ( NASDAQ:NOTV ) shares are down a considerable 32% in the last...Analiz Makalesi • Dec 06
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analiz Makalesi • Apr 26
Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues
The Inotiv, Inc. ( NASDAQ:NOTV ) share price has softened a substantial 57% over the previous 30 days, handing back...Analiz Makalesi • Mar 19
Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Feb 13
Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Inotiv, Inc. ( NASDAQ:NOTV ) shares have continued their recent momentum with a 34% gain in the last month alone...Analiz Makalesi • Dec 18
Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company
Those holding Inotiv, Inc. ( NASDAQ:NOTV ) shares would be relieved that the share price has rebounded 61% in the last...Analiz Makalesi • Dec 13
Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81
It's been a sad week for Inotiv, Inc. ( NASDAQ:NOTV ), who've watched their investment drop 19% to US$2.55 in the week...Analiz Makalesi • Nov 21
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Aug 14
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Hissedar Getirileri
| NOTV.Q | US Life Sciences | US Pazar | |
|---|---|---|---|
| 7D | -69.9% | -2.3% | -2.4% |
| 1Y | -97.7% | 7.3% | 21.5% |
Getiri vs. Endüstri: NOTV.Q geçen yıl % 7.3 oranında getiri sağlayan US Life Sciences sektörünün gerisinde kaldı.
Getiri vs Piyasa: NOTV.Q geçen yıl % 21.5 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| NOTV.Q volatility | |
|---|---|
| NOTV.Q Average Weekly Movement | 42.0% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: NOTV.Q hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: NOTV.Q 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 25% dan 42% a yükseldi.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1974 | 1,996 | Bob Leasure | www.inotiv.com |
Inotiv, Inc. Amerika Birleşik Devletleri, Hollanda ve uluslararası alanda ilaç ve tıbbi cihaz endüstrilerine klinik olmayan ve analitik ilaç keşif ve geliştirme hizmetleri sunmaktadır. Şirket, Keşif ve Güvenlik Değerlendirmesi (DSA) ve Araştırma Modelleri ve Hizmetleri (RMS) olmak üzere iki segmentte faaliyet göstermektedir. DMS segmenti, şirketin BASi ürün grubu altında ilaç şirketleri, üniversiteler, devlet araştırma merkezleri ve tıbbi araştırma kurumları tarafından kullanılmak üzere yaşam bilimleri araştırmaları için bilimsel araçlar ve ilgili yazılımları üretmektedir.
Inotiv, Inc. Temel Bilgiler Özeti
| NOTV.Q temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$1.74m |
| Kazançlar(TTM) | -US$86.97m |
| Gelir(TTM) | US$507.36m |
0.0x
P/S Oranı0.0x
F/K OranıNOTV.Q aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| NOTV.Q gelir tablosu (TTM) | |
|---|---|
| Gelir | US$507.36m |
| Gelir Maliyeti | US$390.95m |
| Brüt Kâr | US$116.41m |
| Diğer Giderler | US$203.38m |
| Kazançlar | -US$86.97m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -2.49 |
| Brüt Marj | 22.94% |
| Net Kâr Marjı | -17.14% |
| Borç/Özkaynak Oranı | 549.2% |
NOTV.Q uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/12 21:06 |
| Gün Sonu Hisse Fiyatı | 2026/06/11 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/09/30 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Inotiv, Inc. 5 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| David Windley | Jefferies LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |